Journal of clinical gastroenterology · 2025
Comparative Analysis of ERCP and PTBD for Biliary Interventions for Readmission Rates and Patient Outcomes.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Daniel Huai-En, Chang Patrick, Tintara Supisara, Chang Frederick, Phan Jennifer
Аннотация
BACKGROUND: Endoscopic retrograde cholangiopancreatography (ERCP) and percutaneous transhepatic biliary drainage (PTBD) are interventions used to relieve biliary obstruction. The utility of ERCP compared with PTBD is not fully understood from a utilization outcome standpoint. Our study compares readmission rates and hospitalization outcomes in ERCP and PTBD.
METHODS: Using the National Readmission Database (NRD) 2016 to 2020, we identified all patients with an ERCP or PTBD completed during admission. The study cohort was first analyzed by 3 weighted study arms including those admitted with cholangitis, biliary/pancreatic malignancy, and choledocholithiasis. Second, we analyzed the cohort by a 1:1, unweighted propensity match. The primary outcome was 30 day, 90 day, and 6 month readmission. Secondary outcomes were readmission/overall mortality, cost, and length of stay. Outcomes were analyzed using multivariate analysis.
RESULTS: A total of 621,735 admissions were identified associated with 589,796 ERCP and 31,939 PTBD. In the propensity matched cohort, PTBD had a higher readmission rate at 30 days (20.38% vs. 13.71% P <0.0001), 90 days (14.63% vs. 13.14%, P <0.0001) but lower rate at 6 months (8.50% vs. 9.67%, P =0.0003). Secondary outcomes included increased PTBD-associated hospital length of stay (9.01 d vs. 6.74 d, P <0.0001), hospitalization cost ($106,947.97 vs. $97,602.25, P <0.0001), and overall mortality (6.86% vs. 4.35%, P <0.0001). No major differences were found for mortality among readmissions at 30 days (7.19% vs. 6.88%, P =0.5382), 90 day (6.82% vs. 6.51%, P =0.5612), and 6 months (5.08% vs. 5.91%, P =0.1744).
CONCLUSIONS: ERCP demonstrated superior results compared with PTBD for readmission rates, length of stay and overall mortality. For failed ERCP cases, emerging data for Endoscopic ultrasound guided-biliary drainage (EUS-BD) offers potential over PTBD and may provide additional options for the future in tertiary referral centers with experience.
METHODS: Using the National Readmission Database (NRD) 2016 to 2020, we identified all patients with an ERCP or PTBD completed during admission. The study cohort was first analyzed by 3 weighted study arms including those admitted with cholangitis, biliary/pancreatic malignancy, and choledocholithiasis. Second, we analyzed the cohort by a 1:1, unweighted propensity match. The primary outcome was 30 day, 90 day, and 6 month readmission. Secondary outcomes were readmission/overall mortality, cost, and length of stay. Outcomes were analyzed using multivariate analysis.
RESULTS: A total of 621,735 admissions were identified associated with 589,796 ERCP and 31,939 PTBD. In the propensity matched cohort, PTBD had a higher readmission rate at 30 days (20.38% vs. 13.71% P <0.0001), 90 days (14.63% vs. 13.14%, P <0.0001) but lower rate at 6 months (8.50% vs. 9.67%, P =0.0003). Secondary outcomes included increased PTBD-associated hospital length of stay (9.01 d vs. 6.74 d, P <0.0001), hospitalization cost ($106,947.97 vs. $97,602.25, P <0.0001), and overall mortality (6.86% vs. 4.35%, P <0.0001). No major differences were found for mortality among readmissions at 30 days (7.19% vs. 6.88%, P =0.5382), 90 day (6.82% vs. 6.51%, P =0.5612), and 6 months (5.08% vs. 5.91%, P =0.1744).
CONCLUSIONS: ERCP demonstrated superior results compared with PTBD for readmission rates, length of stay and overall mortality. For failed ERCP cases, emerging data for Endoscopic ultrasound guided-biliary drainage (EUS-BD) offers potential over PTBD and may provide additional options for the future in tertiary referral centers with experience.